Sun Pharma settles litigation with Incyte Corp

Sun Pharma settles litigation with Incyte Corp

Sun Pharma settles litigation with Incyte Corp

Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte Corporation

Sun Pharmaceutical launches Leqselvi in US for severe alopecia areata

Leqselvi is an oral drug that selectively inhibits Janus kinases JAK1 and JAK2. It has been approved for adult patients experiencing severe forms of alopecia areata, an autoimmune The post Sun Pharmaceutical launches Leqselvi in US for severe alopecia areata appeared first on Pharmaceutical Business review.

Sun Pharma settles with Incyte Corporation in litigation relating to LEQSELVI - Express Pharma

Sun Pharmaceutical Industries announced that further to its intimation dated April 10, 2025, Sun and Incyte Corporation have entered into a settlement and license agreement regarding litigation related to LEQSELVI (deuruxolitinib). Under the terms of the agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each oth…

Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp

Sun Pharmaceuticals on Monday announced the launch of hair loss drug Leqselvi (deuruxolitinib) in the United States (US) market for the treatment of alopecia areata, a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The announcement came after the Mumbai-based pharma major inked a settlement pact with US-based Incyte Corporation regarding the hair loss drug. Incyt…

Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi

New Delhi, Jul 14 (PTI) Sun Pharmaceutical Industries on Monday said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for severe hair loss. Under the terms of agreement, the parties will seek dismissal of the pending Leqselvi litigation in the US District Court for the District of New Jersey, and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised…